The current Wegovy and Zepbound labels list hair loss as a reported adverse reaction: 3% with Wegovy 2.4 mg versus 1% with placebo [1], and 4% to 5% across Zepbound doses versus 1% with placebo [2]. Both labels say it was associated with weight reduction, and it was reported more often by women [1][2]. The cause is not proven. Shedding triggered by rapid weight loss (telogen effluvium) is the leading hypothesis, and that type usually resolves [5][7].
Key takeaways
- In three Wegovy 2.4 mg trials (2,116 treated adults, up to 68 weeks), hair loss was reported by 3% versus 1% of 1,261 placebo patients [1].
- In the two Zepbound trials the label pools (up to 72 weeks), hair loss was reported by 5% (5 mg), 4% (10 mg) and 5% (15 mg) of patients versus 1% on placebo [2].
- Women reported it far more often: 7.1% of women versus 0.5% of men on Zepbound, and 4% versus 0.9% on Wegovy 2.4 mg [1][2].
- The Ozempic and Mounjaro diabetes labels list alopecia only in postmarketing reports, where a causal link is not always established [3][4].
- Telogen effluvium typically begins about 3 months after a trigger (range 1 to 6 months) and usually lasts under 6 months [7], but regrowth after stopping a GLP-1 specifically is unconfirmed [6].
Do GLP-1 medications cause hair loss?
The Wegovy and Zepbound labels list hair loss as an adverse reaction seen in clinical trials, so it is a recognized effect of those medicines, although the mechanism is not proven [1][2]. Both labels say that hair loss in treated patients was associated with weight reduction [1][2]. Hair loss does not appear in the Warnings and Precautions section of the Wegovy label [1].
The diabetes versions of the same drugs read differently. The Ozempic (semaglutide) and Mounjaro (tirzepatide) labels do not include hair loss in their clinical trial adverse reaction tables. They list alopecia only in the postmarketing section, which compiles voluntary reports, and the Ozempic label notes that a causal relationship is not always established for such reports [3][4].
This article describes what published labels and studies report. It cannot tell any individual reader whether hair loss will happen to them or what is causing it.
How common is hair loss on the Wegovy and Zepbound labels?
In the label trial tables, 3% to 5% of people taking the medicine reported hair loss at the weight-management doses studied, versus 1% on placebo [1][2]. The tables list reactions reported by at least 2% of treated patients and more often than with placebo [1][2].
| Label and trial group | Treated patients | Placebo |
|---|---|---|
| Wegovy 2.4 mg, adults, 3 trials up to 68 weeks (N=2,116 treated, 1,261 placebo) [1] | 3% | 1% |
| Wegovy 2.4 mg, adolescents aged 12 and older (N=133 treated, 67 placebo) [1] | 4% | 0% |
| Wegovy 7.2 mg group, adult trial (N=1,311; 2.4 mg comparison group N=304; placebo N=303) [1] | 6% (3% on 2.4 mg) | 1% |
| Zepbound 5 mg, Studies 1 and 2, up to 72 weeks (N=630) [2] | 5% | 1% (N=958) |
| Zepbound 10 mg, same studies (N=948) [2] | 4% | 1% |
| Zepbound 15 mg, same studies (N=941) [2] | 5% | 1% |
Read in absolute terms, the gap between treated and placebo groups was about 2 percentage points for Wegovy 2.4 mg (3% versus 1%) and 3 to 4 points for Zepbound (4% to 5% versus 1%) [1][2]. That means most trial participants, roughly 95% to 97% of those on treatment, did not report hair loss as an adverse reaction [1][2]. These figures come from trials of up to 68 or 72 weeks in adults with obesity or overweight, and they describe groups, not what any one person should expect [1][2].
Both labels also list hair loss among the most common adverse reactions in their Highlights sections [1][2]. The Zepbound Highlights set that list at 5% or more of treated patients [2].
In the Wegovy 7.2 mg trials, the label states hair loss was reported in 5.8% of patients on 7.2 mg, 3.3% on 2.4 mg and 1.0% on placebo. In the 7.2 mg group, one event led to permanent discontinuation, one to temporary interruption and five to dose reduction, versus none of those actions in the other groups [1]. In Zepbound Studies 1 and 2, no Zepbound-treated patient and one placebo patient stopped study treatment because of hair loss [2].
Who reports it more often?
Women reported hair loss several times more often than men in both labels [1][2]. In the pooled Wegovy 2.4 mg trials, hair loss was reported by 4% of women and 0.9% of men on the medicine, versus 2% of women and 0% of men on placebo [1]. For Zepbound, the label reports 7.1% of women and 0.5% of men on treatment, versus 1.3% of women and 0% of men on placebo [2].
Source: [1][2] Wegovy and Zepbound prescribing information, Section 6.1. Different trials, so bars are not head-to-head comparisons.
The labels do not explain the sex difference. A 2026 systematic review lists greater weight loss in women as one possibility and says reporting differences may also contribute, and it calls the question unclear [5].
What do other trials and observational studies show?
Outside the labels, the evidence is mixed and mostly observational, and the results depend on the study design, the drug and the type of hair loss. A 2026 commentary found no prospective controlled studies and no meta-analyses specifically on this question when it was written [6]. A separate 2026 meta-analysis of 17 studies reported a pooled odds ratio of 1.40 (95% CI 1.33 to 1.48) for any non-scarring alopecia, but only 3 cohort studies contributed to that estimate [12].
| Study | Design | Finding |
|---|---|---|
| SURMOUNT-1 (Jastreboff 2022) [5] | Randomized trial, tirzepatide vs placebo | Alopecia about 5% across doses vs 0.9% (6/643) on placebo |
| Pooled tirzepatide trials [5] | Pooled randomized trials | 5.4% (119/2,183) vs 0.9% (22/2,221) on placebo |
| Burke 2025 [6] | Dermatology clinic cohort, n=283 | No significant link with androgenetic alopecia or telogen effluvium; non-significant trends for semaglutide and tirzepatide |
| Neubauer 2025 [5] | TriNetX cohort, about 218,000 | Telogen effluvium higher on tirzepatide than other weight-loss drugs (HR 2.65); not higher vs bariatric surgery (HR 1.61); no increase for semaglutide or liraglutide |
| Ching 2025 [6] | US national database | Any alopecia OR 1.18; androgenetic alopecia OR 1.80; no link to alopecia areata or telogen effluvium |
| Sodhi 2025 [6] | Canadian claims, semaglutide vs bupropion-naltrexone | Hair loss aHR 1.52 (0.86 to 2.69); interval includes 1 |
Reports to pharmacovigilance databases also flag semaglutide (reporting odds ratio 2.46) and tirzepatide (1.73) [6]. These databases show disproportionate reporting, not how often hair loss occurs, and public attention to the topic may inflate reports [5][6]. Reviewers also note that hair loss is often not prespecified in trials, and that terms such as alopecia are often used without a dermatologist confirming the type [5][6]. An earlier 2025 systematic review found only five eligible studies and could not pool them [11].
Is it the medicine or the weight loss?
Nobody has established which it is. The leading hypothesis is that rapid weight loss and reduced eating trigger telogen effluvium, a diffuse shedding of resting hairs, and the labels' wording that hair loss was associated with weight reduction fits that idea without proving it [1][2][5].
Telogen effluvium is described as a reactive process triggered by metabolic stress, hormonal changes or medications. Listed triggers include crash dieting, low protein intake and iron deficiency. Shedding typically begins about 3 months after the trigger, within a range of 1 to 6 months [7]. The 2026 reviews describe weight loss and nutrition as the most likely contributors, partly by analogy with bariatric surgery, and say it is hard to separate them from any direct drug effect [5][6].
Other explanations have been proposed, with varying support:
- Rapid weight loss and lower calorie intake triggering telogen effluvium: the leading hypothesis, drawn partly from bariatric data [5][7].
- Gaps in protein, iron, zinc or vitamin D: proposed, and difficult to separate from the drug's effect [5].
- A hormonal shift, such as a possible transient rise in bioavailable testosterone promoting follicle miniaturization: one proposed mechanism, with limited evidence of direct androgen effects [5].
- A direct effect on hair follicles: not proven; no human study shows it, and GLP-1 receptors in mouse skin suggest but do not establish a similar effect in people [5][6].
- Metabolic or circadian effects: described as theoretical, without direct evidence [5].
One finding does not fit a simple telogen effluvium timeline: a 2025 study reported a mean of 1.75 years to new alopecia, which the 2026 review authors note is longer than the usual 1 to 6 months [5]. Patterned hair loss (androgenetic alopecia) and alopecia areata are different conditions from telogen effluvium, and studies disagree about whether GLP-1 use is linked to them [6].
Does hair grow back?
For telogen effluvium, hair usually does grow back. Acute telogen effluvium is self-limited, shedding usually lasts under 6 months, and regrowth can take up to about 6 months to begin and longer to notice [7]. A 2026 review reports improvement typically within 3 to 6 months after weight stabilizes and says there is no strong evidence of permanent follicle damage from GLP-1 medications [5].
Two cautions apply. First, whether hair regrows after stopping a GLP-1 specifically has not been confirmed, and drug-triggered alopecia areata may not improve when the drug is withdrawn [6]. Second, other types of hair loss follow different courses and need their own evaluation [6]. Bariatric surgery patients show a similar pattern: a patient-education article reports that hair loss rarely lasts more than 6 months without a dietary cause, and that loss continuing past a year, or beginning after 6 months, may signal a nutritional problem worth checking [9]. That article is from 2011 and is not a controlled study.
Trial discontinuation data are reassuring but limited. In the Zepbound label pool, no treated patient stopped the study drug for hair loss [2]. In the Wegovy 7.2 mg group, one patient permanently discontinued [1].
Do protein and vitamins make a difference?
Nutrition is a plausible factor, but none of the sources reviewed here reports a trial showing that a specific protein intake or supplement prevents GLP-1-related hair loss. MedlinePlus lists a low-protein diet or poor nutrition among causes of hair loss, alongside thyroid disease, certain medicines, stress and family history [10].
A 2025 joint advisory from four obesity and nutrition societies lists excessive hair loss among signs of frank nutrient deficiency. It notes that the adult protein recommended dietary allowance is 0.8 g/kg/day, that higher targets such as 1.2 to 1.6 g/kg/day have been proposed during active weight reduction, and that there is still no consensus on the optimal approach. It recommends re-assessing nutrient levels during therapy [8].
When shedding persists or follows rapid weight loss or restrictive eating, one review suggests a clinician consider basic labs: a complete blood count, ferritin, thyroid-stimulating hormone and vitamin D [5]. Iron saturation may be a more sensitive marker than ferritin, and a normal ferritin does not rule out iron deficiency [7]. Supplements are not risk-free: the 2011 bariatric article warns that high doses of zinc carry toxicity risks and should be used only under supervision [9].
What this means in practice
- Hair loss is a labeled, reported reaction for Wegovy and Zepbound: 3% to 5% in label trial tables versus 1% on placebo [1][2].
- Shedding from a trigger like fast weight loss usually shows up about 3 months later (range 1 to 6 months), so noting when it started helps a clinician sort out the cause [7].
- Hair loss has several possible causes, including thyroid disease, iron deficiency, low protein intake, stress and family history, so the cause should be evaluated rather than assumed [7][10].
- Total food intake and protein are worth reviewing with a clinician or dietitian; higher protein targets during weight loss are proposed, not established [8].
- Avoid starting high-dose supplements on your own, because some, such as zinc, carry toxicity risks at high doses [9].
- Decisions to pause, change or stop a medicine belong to the prescriber; hair loss is not listed under Warnings and Precautions in the Wegovy label [1].
- Patchy loss, patterned thinning, or scalp itching or inflammation points toward a type other than simple shedding and warrants an in-person evaluation [5].
When to talk to a clinician
Raise hair loss with your prescriber or a dermatologist if shedding is heavy or distressing, continues beyond about 6 months, appears in patches or a pattern, comes with scalp itching or inflammation, or is diagnostically unclear. One 2026 review suggests dermatology referral if hair loss lasts beyond 6 to 9 months or shows those features [5]. Also mention it if you are eating very little or losing weight quickly, since both are linked to shedding [7].
At Healthy Weight Loss 4 U, every program begins with a clinician evaluation, and that evaluation is where to raise hair loss, your history, your current medicines and your eating patterns. A licensed clinician decides what testing or changes, if any, are appropriate for you.
Frequently asked questions
Is hair loss a listed side effect of Wegovy?
Is hair loss a listed side effect of Zepbound?
Do the Ozempic and Mounjaro labels list hair loss?
Is GLP-1 hair loss permanent?
Why are women more likely to report hair loss?
Can eating more protein or taking biotin prevent it?
When does GLP-1-related shedding usually start?
Should I stop my medicine if my hair is falling out?
Sources
- WEGOVY (semaglutide) injection and tablets prescribing information (revised 05/2026). U.S. Food and Drug Administration (Novo Nordisk label), 2026. www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s031lbl218316s003lbl.pdf
- ZEPBOUND (tirzepatide) prescribing information (revised 8/2026). DailyMed, U.S. National Library of Medicine (Eli Lilly label), 2026. dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&type=display
- OZEMPIC (semaglutide) prescribing information (revised 05/2026). U.S. Food and Drug Administration (Novo Nordisk label), 2026. www.accessdata.fda.gov/drugsatfda_docs/label/2026/209637s038lbl.pdf
- MOUNJARO (tirzepatide) prescribing information (revised 01/2026). U.S. Food and Drug Administration (Eli Lilly label), 2026. www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866s041lbl.pdf
- GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling. Science Progress (Gupta, Teasell, Economopoulos, Mirmirani), 2026. pmc.ncbi.nlm.nih.gov/articles/PMC13100445
- Hair Loss in Patients on Glucagon-Like Peptide 1 Receptor Agonists: Understanding Risks and Managing Outcomes. Dermatology and Therapy (Piraccini, Vano-Galvan, Blume-Peytavi et al.), commentary, 2026. link.springer.com/article/10.1007/s13555-026-01792-0
- Telogen Effluvium. StatPearls, NCBI Bookshelf (Hughes, Syed, Saleh), 2024. www.ncbi.nlm.nih.gov/books/NBK430848/
- Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity (Mozaffarian et al.), 2025. pmc.ncbi.nlm.nih.gov/articles/PMC12304835
- Weight-loss Surgery, Nutrition and Hair Loss. Obesity Action Coalition (Jacques), 2011. www.obesityaction.org/resources/weight-loss-surgery-nutrition-and-hair-loss/
- Hair Loss. MedlinePlus, National Library of Medicine, n.d.. medlineplus.gov/hairloss.html
- Hair Loss Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use: A Systematic Review. Cureus (Alsuwailem et al.), 2025. pmc.ncbi.nlm.nih.gov/articles/PMC12530271/
- GLP-1 Receptor Agonists and Alopecia: A Systematic Review and Meta-Analysis of Incidence, Risk, Subtypes, and Mechanisms. Skin Appendage Disorders (Viquez Burboa et al.), PubMed record, 2026. pubmed.ncbi.nlm.nih.gov/42621629/
Keep reading
Managing GLP-1 Side Effects: Nausea, Reflux, Red Flags
Read →Protein, Meal Planning and Meal Replacements for Weight Loss
Read →First 12 Weeks on a GLP-1: What to Expect, Per the Labels
Read →Protect Muscle During Weight Loss: What the Evidence Shows
Read →GLP-1 Medications and Mood: What the FDA and Studies Say
Read →Serious Risks of GLP-1 Medications: Gallbladder, Pancreatitis
Read →Questions about your own situation? A clinician can review your history and goals. Related: Personalized Weight Loss Counseling.